A phase three clinical trial determined that a 3-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a single copy of the most common genetic mutation for the disease.
This full article appears on <a href="https://www.sciencedaily.com/releases/2019/10/191031174701.htm">Science Daily</a>